Zentiva Completes Voluntary Tender Offer for APONTIS PHARMA

Zentiva AG, a fully owned subsidiary of Zentiva Pharma GmbH, has successfully completed the voluntary public tender offer for the shares of APONTIS PHARMA AG, a leading pharmaceutical company in Germany. Following the completion of the offer, Zentiva now holds approximately 83.57% of the share capital and about 85.27% of the voting rights of APONTIS PHARMA. The investment agreement between the two companies stipulates the delisting of APONTIS PHARMA's shares from public trading immediately upon settlement of the offer. Zentiva's strategy focuses on providing affordable medications across Europe and aims for sustainable growth through both organic and inorganic means. This acquisition of APONTIS PHARMA aligns with Zentiva's goals of expanding its portfolio, particularly in cardiovascular medicine. While the tender offer is not subject to Germany's WpÜG (Securities Acquisition and Takeover Act), Zentiva reserves the right to acquire additional shares through alternative means. APONTIS PHARMA, known for its innovative single-pill combinations, primarily addresses cardiovascular diseases and aims to improve patient adherence to treatment. The acquisition supports Zentiva's broader strategy of expansion within Europe, emphasizing growth in key therapeutic areas. Zentiva's acquisition does not require a delisting offer under the circumstances, simplifying the process. This transaction highlights Zentiva's ambition to strengthen its position in the pharmaceutical market through strategic acquisitions that enhance its capacity to offer a comprehensive range of healthcare solutions.